Press Releases

Filter Press Releases:



  • Lilly Announces Positive Results for Second Phase 3 Study of Lasmiditan for the Acute Treatment of Migraine

    INDIANAPOLIS, Aug. 4, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that lasmiditan, an investigational, oral, first-in-class molecule for the acute treatment of migraine, met its primary endpoint in SPARTAN, a second Phase 3 study. At two hours following the first dose, a greater percentage of patients treated with lasmiditan were migraine pain-free compared to placebo.…

  • Boehringer Ingelheim and Lilly to support new American College of Cardiology program to highlight the increasingly important role of cardiologists in reducing cardiovascular risk and cardiovascular death in people with type 2 diabetes

    RIDGEFIELD, Conn. and INDIANAPOLIS, July 31, 2017 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced that the companies will support an American College of Cardiology (ACC) program focused on driving quality improvement in cardiology and addressing the latest research advances in the reduction of cardiovascular risk and cardiovascular mortality in people wi…

  • Lilly Reports Second-Quarter Results

    INDIANAPOLIS, July 25, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced financial results for the second quarter of 2017. $ in millions, except per share data Second Quarter % 2017 2016 Change Revenue $ 5,824.3 $ 5,404.8 8% Net Income - Reported 1,008.0 747.7…

  • Lilly and Incyte Provide Update on Baricitinib

    INDIANAPOLIS, July 25, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that a resubmission to the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA) for baricitinib, a once-daily oral medication for the treatment of moderate-to-severe rheumatoid arthritis (RA), will be delayed beyond 2017. The companies will be f…

  • Lilly and Nektar Therapeutics Announce Alliance to Develop and Commercialize NKTR-358, A Novel Autoimmune Therapy

    INDIANAPOLIS and SAN FRANCISCO, July 24, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Nektar Therapeutics (NASDAQ: NKTR) have announced a strategic collaboration to co-develop NKTR-358, a novel immunological therapy discovered by Nektar. NKTR-358, which achieved first human dose in Phase 1 clinical development in March of 2017, has the potential to treat a number of autoimmune and o…

  • Lilly Reaches Settlement Agreement in U.S. Cialis Patent Litigation

    INDIANAPOLIS, July 12, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) has entered into a settlement agreement with generic companies to resolve pending patent litigation in the U.S. District Court for the Eastern District of Virginia regarding the Cialis® (tadalafil) unit dose patent. This patent was previously set to expire on April 26, 2020. As part of the agreement, Cialis exclusi…

  • Eli Lilly and Company to Present More Than 40 Abstracts at the Alzheimer's Association International Conference® 2017 (AAIC® 2017)

    Data highlights include important health outcomes data emphasizing the need for timely detection and management of Alzheimer's disease INDIANAPOLIS, July 12, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced it will present findings from more than 40 research studies at the upcoming Alzheimer's Association International Conference® 2017 (AAIC® 2017) in London…

  • Renowned Television Personality Don Francisco Introduces New Initiative to Help Dispel Myths About Diabetes and Insulin Treatment

    INDIANAPOLIS and RIDGEFIELD, Conn., July 10, 2017 /PRNewswire/ -- Popular television host and legendary entertainer, Don Francisco, is joining Lilly and Boehringer Ingelheim to launch a new awareness initiative, Basado en Hechos, to help address common misconceptions about type 2 diabetes and insulin treatment. As part of this partnership, Don Francisco, who is known for his ability to connec…

  • FDA Grants Priority Review for Lilly's Abemaciclib for the Treatment of Advanced Breast Cancer

    INDIANAPOLIS, July 10, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has accepted and filed its New Drug Application (NDA) for abemaciclib, a cyclin-dependent kinase (CDK)4 & 6 inhibitor, and given the NDA a Priority Review designation. The NDA includes the company's submission of abemaciclib for two indications: abemacicli…

  • UK Supreme Court Rules In Lilly's Favor On Alimta Vitamin Regimen Patents

    INDIANAPOLIS, July 7, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the UK Supreme Court has decided in the litigation relating to alternative salt forms of Alimta® (pemetrexed disodium) that Actavis's products directly infringe Lilly's vitamin regimen patents in the UK, France, Italy and Spain. The UK Supreme Court also affirmed the indirect infringement findin…

  • Lilly Confirms Date and Conference Call for Second-Quarter 2017 Financial Results Announcement

    INDIANAPOLIS, July 6, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its financial results for the second quarter of 2017 on Tuesday, July 25, 2017. Lilly will also conduct a conference call on that day with the investment community and media to further detail the company's financial performance. The conference call will begin at 9 a.m. Eastern time. Investors, media and…

  • Lilly and Purdue University Announce Strategic Research Collaboration

    INDIANAPOLIS and WEST LAFAYETTE, Ind., July 6, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Purdue University today announced a strategic collaboration to conduct life science research. The five-year agreement, where Lilly will provide up to $52 million, marks Purdue's largest strategic collaboration with a single company. "Purdue has enjoyed a long history of engagement with Lil…

  • Japan Ministry of Health, Labor and Welfare (MHLW) Grants Marketing Approval For Olumiant® (baricitinib) for the Treatment of Rheumatoid Arthritis

    INDIANAPOLIS, July 3, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that Japan's Ministry of Health, Labor and Welfare (MHLW) granted marketing approval for Olumiant® (baricitinib) 2-mg and 4-mg tablets for the treatment of rheumatoid arthritis (RA) (including the prevention of structural injury of joints) in patients with inadeq…

  • Lilly Diabetes Brings an Extra Splash of Summertime Fun and Inspiration to Diabetes Camps with Launch of Annual Camp Care Package Speaker Tour

    INDIANAPOLIS, June 27, 2017 /PRNewswire/ -- For the 22,000 children who attend diabetes camp each year, feelings of isolation that may accompany type 1 diabetes can be overcome by fun experiences and new friends who say, "you are not alone." Lilly Diabetes understands the importance of the diabetes camp experience for those taking the first steps toward self-management and increased self-confiden…

  • Eli Lilly and Company Unveils Expanded Biotechnology Center in San Diego

    INDIANAPOLIS, June 21, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced completion of a $90 million expansion of its Biotechnology Center in San Diego, California. Lilly's new space will help foster and accelerate the discovery of medicines within the company's core therapeutic areas of immunology, diabetes, oncology and neurodegeneration, as well as the emerging area of pai…

  • Lilly Declares Third-Quarter 2017 Dividend

    INDIANAPOLIS, June 19, 2017 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2017 of $0.52 per share on outstanding common stock. The dividend is payable September 8, 2017, to shareholders of record at the close of business on August 15, 2017. About Eli Lilly and Company Lilly is a global healthcare leader that uni…

  • EULAR 2017: Lilly's Taltz® (ixekizumab) Demonstrated No Progression or Minimal Progression of Radiographic Disease in Patients with Psoriatic Arthritis Through 52 Weeks

    INDIANAPOLIS, June 16, 2017 /CNW/ -- Eli Lilly and Company (NYSE: LLY) announced today that the majority of patients with active psoriatic arthritis (PsA) treated with Taltz® (ixekizumab) exhibited either no progression or minimal progression of radiographic structural joint damage through 52 weeks of treatment. Detailed results from the extension period of the SPIRIT-P1 trial will be presen…

  • New Safety and Long-Term Efficacy Data from Baricitinib Clinical Trials in Patients with Moderate-to-Severe Rheumatoid Arthritis Presented at EULAR 2017

    INDIANAPOLIS, June 16, 2017 /CNW/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today announced a new pooled analysis of data from eight Olumiant® (baricitinib) clinical trials, showing that baricitinib-treated and placebo-treated patients with moderate-to-severe rheumatoid arthritis (RA) had similar rates of serious infection incidents. Additionally, new data fr…

  • EULAR 2017: Lilly's Taltz® (ixekizumab) Demonstrated Significant Improvements in Disease Signs and Symptoms at 24 Weeks Among Patients with Active Psoriatic Arthritis Who Had Prior Inadequate Response or Intolerance to TNF Inhibitors

    Taltz also demonstrated significant improvements in key secondary measures at 24 weeks INDIANAPOLIS, June 15, 2017 /CNW/ -- Eli Lilly and Company (NYSE: LLY) announced today that patients with active psoriatic arthritis (PsA) who had inadequate response to one or two TNF inhibitors or were intolerant of TNF inhibitors treated with Taltz® (ixekizumab) achieved significant improvement…

  • IDF, in partnership with Lilly, announces second phase of BRIDGES programme funding for translational research in diabetes with focus on secondary prevention

    BRUSSELS and INDIANAPOLIS, June 9, 2017 /PRNewswire/ -- More than 400 million people are living with diabetes. In a further effort to help spread lessons learned from clinical research to benefit people affected by this condition, the International Diabetes Federation (IDF) and Eli Lilly and Company (NYSE: LLY) have come together for the second phase of the Bringing Research in Diabetes to Global…

  • Lilly Announces Webcast to Discuss Pain Management Portfolio

    INDIANAPOLIS, June 8, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will conduct a webcast on Monday, June 19, 2017, to discuss the company's pain management portfolio, including data from three Phase 3 studies of galcanezumab, an investigational treatment for the prevention of episodic and chronic migraine, and data from one Phase 3 study of lasmiditan, an investigational treatment for…

  • Lilly Announces Strategic Collaboration with KeyBioscience AG

    STANS, Switzerland and INDIANAPOLIS, June 8, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and KeyBioscience AG have agreed to a new collaboration focused on the development of Dual Amylin Calcitonin Receptor Agonists (DACRAs), a potential new class of treatments for metabolic disorders such as type 2 diabetes, the companies announced today.  The collaboration includes access to the…

  • Derica Rice to Retire as Lilly Chief Financial Officer

    INDIANAPOLIS, June 1, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that Derica Rice, executive vice president global services and chief financial officer, will retire at the end of December 2017 after 27 years of service with the company. Rice is also a member of Lilly's executive committee. "On behalf of our shareholders, our board,…

  • Lilly to Participate in Goldman Sachs Global Healthcare Conference

    INDIANAPOLIS, May 31, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will participate in the Goldman Sachs 38th Annual Global Healthcare Conference on Wednesday, June 14, 2017. Sue Mahony, Ph.D., senior vice president and president of Lilly Oncology and Levi Garraway, M.D., Ph.D., senior vice president of global development and medical affairs for Lilly Oncology will participate in a fires…

  • Actress Angela Bassett joins For Your SweetHeart™ to urge people with diabetes to know their heart disease risk -- in honor of her mom

    RIDGEFIELD, Conn. and INDIANAPOLIS, May 16, 2017 /PRNewswire/ -- Award-winning actress Angela Bassett, along with 11 leading patient and professional organizations, is joining For Your SweetHeart™: Where diabetes and heart disease meet — a nationwide movement to raise awareness of the critical link between type 2 diabetes and heart disease, the number one killer of people with type 2…

  • Lilly to Participate in Bernstein Strategic Decisions Conference

    INDIANAPOLIS, May 10, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will attend the Bernstein Strategic Decisions Conference on Wednesday, May 31, 2017. David A. Ricks, Lilly's president and chief executive officer, will participate in a fireside chat at 10 a.m., Eastern Time. A live audio webcast will be available on the "Webcasts & Presentations" section of Lilly's Investor website…

  • Leigh Ann Pusey Joins Lilly as Senior Vice President of Corporate Affairs and Communications

    INDIANAPOLIS, May 10, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that Leigh Ann Pusey will be joining Lilly as senior vice president of corporate affairs and communications, effective June 12, 2017. She will be a member of Lilly's executive committee reporting directly to president and chief executive officer, David A. Ricks. Pusey currently serves as president and…

  • Lilly to Participate in UBS Global Healthcare Conference

    INDIANAPOLIS, May 3, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will attend the UBS Global Healthcare Conference on Tuesday, May 23, 2017. Derica Rice, Lilly's executive vice president for global services and chief financial officer, will participate in a fireside chat at 11 a.m., Eastern Time. A live audio webcast will be available on the "Webcasts & Presentations" section of Lil…

  • Lilly Announces Webcast to Discuss Oncology Pipeline

    INDIANAPOLIS, May 2, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will conduct a webcast on Saturday, June 3, 2017, to discuss the company's oncology pipeline, including data from the MONARCH 2 study of abemaciclib in patients with hormone-receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer, which will be presented at the American So…

  • Lilly Declares Second-Quarter 2017 Dividend

    INDIANAPOLIS, May 1, 2017 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the second quarter of 2017 of $0.52 per share on outstanding common stock. The dividend is payable June 9, 2017, to shareholders of record at the close of business on May 15, 2017. About Eli Lilly and CompanyLilly is a global healthcare leader that unites caring…

  • Lilly Reports First-Quarter 2017 Results

    INDIANAPOLIS, April 25, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced financial results for the first quarter of 2017.   $ in millions, except per share data First Quarter % 2017 2016 Change Revenue $ 5,228.3 $ 4,865.1 7 % Net Income (Loss) - Reported (110.8)…

  • Lilly and Ohio University Heritage College of Osteopathic Medicine Partner on Rotation Program for Medical Students

    INDIANAPOLIS, April 4, 2017 /PRNewswire/ -- Students from Ohio University's Heritage College of Osteopathic Medicine will soon join Eli Lilly and Company's (NYSE: LLY) innovative rotation program for aspiring physicians. Launched in early 2014, the program provides students with hands-on experience in a range of pharmaceutical business activities, from drug discovery and development to bioethics…

  • Eli Lilly and Company Sponsors Arthritis Foundation 'Living Your Yes With RA,' an Initiative to Provide Resources for the Rheumatoid Arthritis Community

    INDIANAPOLIS, Oct. 12, 2016 /PRNewswire/ -- Supported by Eli Lilly and Company (NYSE: LLY), the Arthritis Foundation is launching 'Living Your Yes With RA,' a new initiative designed to empower people living with rheumatoid arthritis (RA) by giving them tools, education and resources, allowing them to expect more from their RA treatment - seeking remission or low disease activity as the only acce…

  • Lilly's First Volunteer Teams of 2016 Depart in May for Thailand and Ghana

    INDIANAPOLIS, May 19, 2016 /PRNewswire/ -- A team of Eli Lilly and Company (NYSE: LLY) volunteers from its operations worldwide is on the ground in Thailand, working with a local hospital and health volunteers as part of Lilly's Connecting Hearts Abroad global employee volunteer program. A second team of volunteers will depart next week to serve in Ghana. Nine more teams of Lilly volunteers will…

  • Lilly and United Way Celebrate Deepening Partnership, Community Impact

    INDIANAPOLIS, Nov. 5, 2015 /PRNewswire/ -- Representatives from Eli Lilly and Company (NYSE: LLY) and United Way and its partner agencies gathered today to celebrate the early success of a new partnership approach that includes pairing Lilly teams with United Way agencies and a record gift of $13 million. The results will be shared today from 4-6 p.m. at an Impact Celebration event hosted at the…

  • Diabetes Scholars Foundation Announces 2015 Scholarship Recipients

    ROLLING MEADOWS, Ill. and INDIANAPOLIS, June 25, 2015 /PRNewswire/ -- Attending college is a critical milestone in the lives of many young people. But balancing college life and a full course load while keeping a chronic disease such as diabetes in check can make an exciting time much more challenging. Today, the Diabetes Scholars Foundation (Foundation) announced its 2015 college scholarship rec…

  • Olympian Kris Freeman and NASCAR Driver Ryan Reed to Share Their Courageous Stories with Children Who Have Type 1 Diabetes

    INDIANAPOLIS, June 8, 2015 /PRNewswire/ -- Olympic cross-country skier Kris Freeman and NASCAR XFINITY Series driver Ryan Reed will travel across the U.S. this summer to share their stories of perseverance and triumph as part of the Lilly Camp Care Package (LCCP) program. Kris and Ryan will speak to children at select diabetes summer camps about how type 1 diabetes did not stop them from chasing…

  • Lilly commits 780,000 additional vials of insulin to Life for a Child

    INDIANAPOLIS, June 4, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) has committed another 780,000 vials of insulin to the International Diabetes Federation's Life for a Child program. Life for a Child provides free, life-saving medicine to children living in impoverished communities who otherwise would not have access to the insulin they need. The International Diabetes Federation (IDF) i…

  • Lilly Sends Employees to Serve in Vulnerable Communities around the World

    INDIANAPOLIS, May 27, 2015 /PRNewswire/ -- Marcio Donatelli, a senior marketing associate with the animal health division of Eli Lilly and Company (NYSE: LLY), believes his volunteer work in a healthcare setting in Bangkok, Thailand, will be among the most humbling experiences of his life. "Caring for people in need with respect and dignity is the guiding star for me and my fellow volunteers," sh…

  • Lilly Releases Corporate Responsibility, Global Health Reports

    INDIANAPOLIS, May 4, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today released two new reports that provide a comprehensive overview of the company's corporate responsibility efforts. The reports highlight how Lilly is evolving its approach to corporate responsibility by increasingly leveraging its assets and capabilities in partnership with others to have greater, more sustainable im…